Peptide and Anticoagulant Drugs Market – Global Industry Analysis and Forecast (2023-2029)

Peptide and Anticoagulant Drugs Market size was valued US$ 1.71 Bn. in 2022 and the total revenue is expected to grow at 9.3% through 2023 to 2029, reaching nearly US$ 3.2 Bn.

Global Peptide and Anticoagulant Drugs Market Definition

Peptide drug is probably to have a large range of uses in treating various diseases to illustrate cancer, cardiovascular, pathology, coagulation disorders and diabetes. Anticoagulant is a chemical ingredient that reduces or avoids prolonging the clotting time, coagulation of blood.Peptide and Anticoagulant Drugs MarketTo know about the Research Methodology:- Request Free Sample Report

Global Peptide and Anticoagulant Drugs Market Dynamics

Global peptide and anticoagulant drugs market is estimated to witness lucrative growth over 2022-2029 because of growing cases of peptide and anticoagulant drugs which create an opportunity for the pharmacy companies to introduce new therapy. In 2017, as per the WHO diabetes patients has increased from 108 Mn. in 1980 to 422 Mn. in 2017. Worldwide prevalence of diabetes in adults above 18 years of age has increased from nearly 4.7% in 1980 toward 8.5% in 2017. Similarly, forecast that breast cancer rates are utmost in non-Hispanic white females, breast cancer death rates are maximum in American and African females which upsurge the growth of the market for peptide and anticoagulant drugs during the forecast period. On the other hand, the high degree of market consolidation and availability of alternative drugs are restraining the growth of the peptide and anticoagulant drugs market globally. Such as the major companies in the market are large and well established & enjoy a high grade of product loyalty.

Global Peptide and Anticoagulant Drugs Market Segment Analysis

The MMR report will provide an accurate prediction of the contribution of the various segments to the growth of the peptide and anticoagulant drugs market size. By application, the diabetes segment is expected to continue to hold the largest XX% share in market owing to the rising incidence and prevalence of diabetes cases in the various major economies.

Regional Analysis

North America market was valued US$ XX million in 2022 and is expected to reach a value of US$ XX million by 2029, with a CAGR of XX.20% during the forecast period. This is because of the growing innovations in cancer research, clinical practice, and access to cancer treatment in the USA. According, to the World Health Organization, diabetes was the cause of approximately 1.6 million deaths. Maximum of all deaths as of high blood glucose rise before the age of 70 years. However, Europe accounts for the second-highest revenue share contribution to the market due to the growing use of tobacco. As per the U.K. Cancer Research, 359,960 cancer cases were found in 2017.

Global Peptide and Anticoagulant Drugs Market Competitive Landscape

The competitive landscape section in the market offers a deep dive into the profiles of the leading companies operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the key players having a stronghold in the peptide and anticoagulant drugs market. The objective of the report is to present a comprehensive analysis of the Global market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Peptide and Anticoagulant Drugs Market dynamics, structure by analyzing the market segments and projects the Global market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global market make the report investor’s guide.

Global Peptide and Anticoagulant Drugs Market Scope: Inquire before buying

Global Peptide and Anticoagulant Drugs Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2018 to 2022 Market Size in 2022: US $ 1.71 Bn.
Forecast Period 2023 to 2029 CAGR: 9.3% Market Size in 2029: US $ 3.2 Bn.
Segments Covered: by Type Antifungal Hormonal Ace Inhibitors Antibiotic Other Drugs
by Low Molecular Weight Heparin Type Heparin Sodium Enoxaparin Sodium Dalteparin Sodium Fondaparinux
by Application Infectious Diseases Gynecology Cancer Diabetes Cardiology Osteoporosis Others

Global Peptide and Anticoagulant Drugs Market, by Region

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)

Key players

1. Celsus 2. Baxter 3. Alkem Laboratories Limited 4. Hemmo Pharma 5. Biofer 6. Wockhardt 7. AmbioPharm 8. Bachem 9. Cadila Pharmaceuticals 10.Sun Pharmaceutical Industries 11.Pfizer 12.Abbott Laboratories 13.Leo Pharma 14.Aspen 15.Takeda 16.Teva 17.Sanofi 18.Eli Lilly 19.Novo Nordisk 20.Cipla Limited 21.Biocon Limited Frequently Asked Questions: 1. Which region has the largest share in Global Peptide and Anticoagulant Drugs Market? Ans: North American region holds the highest share in 2022. 2. What is the growth rate of Global Peptide and Anticoagulant Drugs Market? Ans: The Global market is growing at a CAGR of 9.3% during forecasting period 2023-2029. 3. What is scope of the Global Peptide and Anticoagulant Drugs market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Peptide and Anticoagulant Drugs market? Ans: The important key players in the Global market are – Celsus, Baxter, Alkem Laboratories Limited, Hemmo Pharma, Biofer, Wockhardt, AmbioPharm, Bachem, Cadila Pharmaceuticals, Sun Pharmaceutical Industries, Pfizer, Abbott Laboratories, Leo Pharma, Aspen, Takeda, Teva, Sanofi, Eli Lilly, Novo Nordisk, Cipla Limited, and Biocon Limited 5. What is the study period of this market? Ans: The Global market is studied from 2022 to 2029.
Global Peptide and Anticoagulant Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Peptide and Anticoagulant Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Peptide and Anticoagulant Drugs Market Analysis and Forecast 6.1. Peptide and Anticoagulant Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Peptide and Anticoagulant Drugs Market Analysis and Forecast, By Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Peptide and Anticoagulant Drugs Market Value Share Analysis, By Type 7.4. Peptide and Anticoagulant Drugs Market Size (US$ Bn) Forecast, By Type 7.5. Peptide and Anticoagulant Drugs Market Analysis, By Type 7.6. Peptide and Anticoagulant Drugs Market Attractiveness Analysis, By Type 8. Global Peptide and Anticoagulant Drugs Market Analysis and Forecast, By Low Molecular Weight Heparin Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Peptide and Anticoagulant Drugs Market Value Share Analysis, By Low Molecular Weight Heparin Type 8.4. Peptide and Anticoagulant Drugs Market Size (US$ Bn) Forecast, By Low Molecular Weight Heparin Type 8.5. Peptide and Anticoagulant Drugs Market Analysis, By Low Molecular Weight Heparin Type 8.6. Peptide and Anticoagulant Drugs Market Attractiveness Analysis, By Low Molecular Weight Heparin Type 9. Global Peptide and Anticoagulant Drugs Market Analysis and Forecast, By Application 9.1. Introduction and Definition 9.2. Key Findings 9.3. Peptide and Anticoagulant Drugs Market Value Share Analysis, By Application 9.4. Peptide and Anticoagulant Drugs Market Size (US$ Bn) Forecast, By Application 9.5. Peptide and Anticoagulant Drugs Market Analysis, By Application 9.6. Peptide and Anticoagulant Drugs Market Attractiveness Analysis, By Application 10. Global Peptide and Anticoagulant Drugs Market Analysis, by Region 10.1. Peptide and Anticoagulant Drugs Market Value Share Analysis, by Region 10.2. Peptide and Anticoagulant Drugs Market Size (US$ Bn) Forecast, by Region 10.3. Peptide and Anticoagulant Drugs Market Attractiveness Analysis, by Region 11. North America Peptide and Anticoagulant Drugs Market Analysis 11.1. Key Findings 11.2. North America Peptide and Anticoagulant Drugs Market Overview 11.3. North America Peptide and Anticoagulant Drugs Market Value Share Analysis, By Type 11.4. North America Peptide and Anticoagulant Drugs Market Forecast, By Type 11.4.1. Antifungal 11.4.2. Hormonal 11.4.3. Ace Inhibitors 11.4.4. Antibiotic 11.4.5. Fondaparinux Drugs 11.5. North America Peptide and Anticoagulant Drugs Market Value Share Analysis, By Low Molecular Weight Heparin Type 11.6. North America Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 11.6.1. Heparin Sodium 11.6.2. Enoxaparin Sodium 11.6.3. Dalteparin Sodium 11.6.4. Fondaparinux 11.7. North America Peptide and Anticoagulant Drugs Market Value Share Analysis, By Application 11.8. North America Peptide and Anticoagulant Drugs Market Forecast, By Application 11.8.1. Infectious Diseases 11.8.2. Gynecology 11.8.3. Cancer 11.8.4. Diabetes 11.8.5. Cardiology 11.8.6. Osteoporosis 11.8.7. Others 11.9. North America Peptide and Anticoagulant Drugs Market Value Share Analysis, by Country 11.10. North America Peptide and Anticoagulant Drugs Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Peptide and Anticoagulant Drugs Market Analysis, by Country 11.12. U.S. Peptide and Anticoagulant Drugs Market Forecast, By Type 11.12.1. Antifungal 11.12.2. Hormonal 11.12.3. Ace Inhibitors 11.12.4. Antibiotic 11.12.5. Fondaparinux Drugs 11.13. U.S. Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 11.13.1. Heparin Sodium 11.13.2. Enoxaparin Sodium 11.13.3. Dalteparin Sodium 11.13.4. Fondaparinux 11.14. U.S. Peptide and Anticoagulant Drugs Market Forecast, By Application 11.14.1. Infectious Diseases 11.14.2. Gynecology 11.14.3. Cancer 11.14.4. Diabetes 11.14.5. Cardiology 11.14.6. Osteoporosis 11.14.7. Others 11.15. Canada Peptide and Anticoagulant Drugs Market Forecast, By Type 11.15.1. Antifungal 11.15.2. Hormonal 11.15.3. Ace Inhibitors 11.15.4. Antibiotic 11.15.5. Fondaparinux Drugs 11.16. Canada Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 11.16.1. Heparin Sodium 11.16.2. Enoxaparin Sodium 11.16.3. Dalteparin Sodium 11.16.4. Fondaparinux 11.17. Canada Peptide and Anticoagulant Drugs Market Forecast, By Application 11.17.1. Infectious Diseases 11.17.2. Gynecology 11.17.3. Cancer 11.17.4. Diabetes 11.17.5. Cardiology 11.17.6. Osteoporosis 11.17.7. Others 11.18. North America Peptide and Anticoagulant Drugs Market Attractiveness Analysis 11.18.1. By Type 11.18.2. By Low Molecular Weight Heparin Type 11.18.3. By Application 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Peptide and Anticoagulant Drugs Market Analysis 12.1. Key Findings 12.2. Europe Peptide and Anticoagulant Drugs Market Overview 12.3. Europe Peptide and Anticoagulant Drugs Market Value Share Analysis, By Type 12.4. Europe Peptide and Anticoagulant Drugs Market Forecast, By Type 12.4.1. Antifungal 12.4.2. Hormonal 12.4.3. Ace Inhibitors 12.4.4. Antibiotic 12.4.5. Fondaparinux Drugs 12.5. Europe Peptide and Anticoagulant Drugs Market Value Share Analysis, By Low Molecular Weight Heparin Type 12.6. Europe Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 12.6.1.1. Heparin Sodium 12.6.1.2. Enoxaparin Sodium 12.6.1.3. Dalteparin Sodium 12.6.1.4. Fondaparinux 12.7. Europe Peptide and Anticoagulant Drugs Market Value Share Analysis, By Application 12.8. Europe Peptide and Anticoagulant Drugs Market Forecast, By Application 12.8.1. Infectious Diseases 12.8.2. Gynecology 12.8.3. Cancer 12.8.4. Diabetes 12.8.5. Cardiology 12.8.6. Osteoporosis 12.8.7. Others 12.9. Europe Peptide and Anticoagulant Drugs Market Value Share Analysis, by Country 12.10. Europe Peptide and Anticoagulant Drugs Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Peptide and Anticoagulant Drugs Market Analysis, by Country 12.12. Germany Peptide and Anticoagulant Drugs Market Forecast, By Type 12.12.1. Antifungal 12.12.2. Hormonal 12.12.3. Ace Inhibitors 12.12.4. Antibiotic 12.12.5. Fondaparinux Drugs 12.13. Germany Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 12.13.1. Heparin Sodium 12.13.2. Enoxaparin Sodium 12.13.3. Dalteparin Sodium 12.13.4. Fondaparinux 12.14. Germany Peptide and Anticoagulant Drugs Market Forecast, By Application 12.14.1. Infectious Diseases 12.14.2. Gynecology 12.14.3. Cancer 12.14.4. Diabetes 12.14.5. Cardiology 12.14.6. Osteoporosis 12.14.7. Others 12.15. U.K. Peptide and Anticoagulant Drugs Market Forecast, By Type 12.15.1. Antifungal 12.15.2. Hormonal 12.15.3. Ace Inhibitors 12.15.4. Antibiotic 12.15.5. Fondaparinux Drugs 12.16. U.K. Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 12.16.1. Heparin Sodium 12.16.2. Enoxaparin Sodium 12.16.3. Dalteparin Sodium 12.16.4. Fondaparinux 12.17. U.K. Peptide and Anticoagulant Drugs Market Forecast, By Application 12.17.1. Infectious Diseases 12.17.2. Gynecology 12.17.3. Cancer 12.17.4. Diabetes 12.17.5. Cardiology 12.17.6. Osteoporosis 12.17.7. Others 12.18. France Peptide and Anticoagulant Drugs Market Forecast, By Type 12.18.1. Antifungal 12.18.2. Hormonal 12.18.3. Ace Inhibitors 12.18.4. Antibiotic 12.18.5. Fondaparinux Drugs 12.19. France Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 12.19.1. Heparin Sodium 12.19.2. Enoxaparin Sodium 12.19.3. Dalteparin Sodium 12.19.4. Fondaparinux 12.20. France Peptide and Anticoagulant Drugs Market Forecast, By Application 12.20.1. Infectious Diseases 12.20.2. Gynecology 12.20.3. Cancer 12.20.4. Diabetes 12.20.5. Cardiology 12.20.6. Osteoporosis 12.20.7. Others 12.21. Italy Peptide and Anticoagulant Drugs Market Forecast, By Type 12.21.1. Antifungal 12.21.2. Hormonal 12.21.3. Ace Inhibitors 12.21.4. Antibiotic 12.21.5. Fondaparinux Drugs 12.22. Italy Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 12.22.1. Heparin Sodium 12.22.2. Enoxaparin Sodium 12.22.3. Dalteparin Sodium 12.22.4. Fondaparinux 12.23. Italy Peptide and Anticoagulant Drugs Market Forecast, By Application 12.23.1. Infectious Diseases 12.23.2. Gynecology 12.23.3. Cancer 12.23.4. Diabetes 12.23.5. Cardiology 12.23.6. Osteoporosis 12.23.7. Others 12.24. Spain Peptide and Anticoagulant Drugs Market Forecast, By Type 12.24.1. Antifungal 12.24.2. Hormonal 12.24.3. Ace Inhibitors 12.24.4. Antibiotic 12.24.5. Fondaparinux Drugs 12.25. Spain Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 12.25.1. Heparin Sodium 12.25.2. Enoxaparin Sodium 12.25.3. Dalteparin Sodium 12.25.4. Fondaparinux 12.26. Spain Peptide and Anticoagulant Drugs Market Forecast, By Application 12.26.1. Infectious Diseases 12.26.2. Gynecology 12.26.3. Cancer 12.26.4. Diabetes 12.26.5. Cardiology 12.26.6. Osteoporosis 12.26.7. Others 12.27. Rest of Europe Peptide and Anticoagulant Drugs Market Forecast, By Type 12.27.1. Antifungal 12.27.2. Hormonal 12.27.3. Ace Inhibitors 12.27.4. Antibiotic 12.27.5. Fondaparinux Drugs 12.28. Rest of Europe Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 12.28.1. Heparin Sodium 12.28.2. Enoxaparin Sodium 12.28.3. Dalteparin Sodium 12.28.4. Fondaparinux 12.29. Rest Of Europe Peptide and Anticoagulant Drugs Market Forecast, By Application 12.29.1. Infectious Diseases 12.29.2. Gynecology 12.29.3. Cancer 12.29.4. Diabetes 12.29.5. Cardiology 12.29.6. Osteoporosis 12.29.7. Others 12.30. Europe Peptide and Anticoagulant Drugs Market Attractiveness Analysis 12.30.1. By Type 12.30.2. By Low Molecular Weight Heparin Type 12.30.3. By Application 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Peptide and Anticoagulant Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Peptide and Anticoagulant Drugs Market Overview 13.3. Asia Pacific Peptide and Anticoagulant Drugs Market Value Share Analysis, By Type 13.4. Asia Pacific Peptide and Anticoagulant Drugs Market Forecast, By Type 13.4.1. Antifungal 13.4.2. Hormonal 13.4.3. Ace Inhibitors 13.4.4. Antibiotic 13.4.5. Fondaparinux Drugs 13.5. Asia Pacific Peptide and Anticoagulant Drugs Market Value Share Analysis, By Low Molecular Weight Heparin Type 13.6. Asia Pacific Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 13.6.1.1. Heparin Sodium 13.6.1.2. Enoxaparin Sodium 13.6.1.3. Dalteparin Sodium 13.6.1.4. Fondaparinux 13.7. Asia Pacific Peptide and Anticoagulant Drugs Market Value Share Analysis, By Application 13.8. Asia Pacific Peptide and Anticoagulant Drugs Market Forecast, By Application 13.8.1. Infectious Diseases 13.8.2. Gynecology 13.8.3. Cancer 13.8.4. Diabetes 13.8.5. Cardiology 13.8.6. Osteoporosis 13.8.7. Others 13.9. Asia Pacific Peptide and Anticoagulant Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Peptide and Anticoagulant Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Peptide and Anticoagulant Drugs Market Analysis, by Country 13.12. China Peptide and Anticoagulant Drugs Market Forecast, By Type 13.12.1. Antifungal 13.12.2. Hormonal 13.12.3. Ace Inhibitors 13.12.4. Antibiotic 13.12.5. Fondaparinux Drugs 13.13. China Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 13.13.1. Heparin Sodium 13.13.2. Enoxaparin Sodium 13.13.3. Dalteparin Sodium 13.13.4. Fondaparinux 13.14. China Peptide and Anticoagulant Drugs Market Forecast, By Application 13.14.1. Infectious Diseases 13.14.2. Gynecology 13.14.3. Cancer 13.14.4. Diabetes 13.14.5. Cardiology 13.14.6. Osteoporosis 13.14.7. Others 13.15. India Peptide and Anticoagulant Drugs Market Forecast, By Type 13.15.1. Antifungal 13.15.2. Hormonal 13.15.3. Ace Inhibitors 13.15.4. Antibiotic 13.15.5. Fondaparinux Drugs 13.16. India Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 13.16.1. Heparin Sodium 13.16.2. Enoxaparin Sodium 13.16.3. Dalteparin Sodium 13.16.4. Fondaparinux 13.17. India Peptide and Anticoagulant Drugs Market Forecast, By Application 13.17.1. Infectious Diseases 13.17.2. Gynecology 13.17.3. Cancer 13.17.4. Diabetes 13.17.5. Cardiology 13.17.6. Osteoporosis 13.17.7. Others 13.18. Japan Peptide and Anticoagulant Drugs Market Forecast, By Type 13.18.1. Antifungal 13.18.2. Hormonal 13.18.3. Ace Inhibitors 13.18.4. Antibiotic 13.18.5. Fondaparinux Drugs 13.19. Japan Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 13.19.1. Heparin Sodium 13.19.2. Enoxaparin Sodium 13.19.3. Dalteparin Sodium 13.19.4. Fondaparinux 13.20. Japan Peptide and Anticoagulant Drugs Market Forecast, By Application 13.20.1. Infectious Diseases 13.20.2. Gynecology 13.20.3. Cancer 13.20.4. Diabetes 13.20.5. Cardiology 13.20.6. Osteoporosis 13.20.7. Others 13.21. ASEAN Peptide and Anticoagulant Drugs Market Forecast, By Type 13.21.1. Antifungal 13.21.2. Hormonal 13.21.3. Ace Inhibitors 13.21.4. Antibiotic 13.21.5. Fondaparinux Drugs 13.22. ASEAN Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 13.22.1. Heparin Sodium 13.22.2. Enoxaparin Sodium 13.22.3. Dalteparin Sodium 13.22.4. Fondaparinux 13.23. ASEAN Peptide and Anticoagulant Drugs Market Forecast, By Application 13.23.1. Infectious Diseases 13.23.2. Gynecology 13.23.3. Cancer 13.23.4. Diabetes 13.23.5. Cardiology 13.23.6. Osteoporosis 13.23.7. Others 13.24. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Forecast, By Type 13.24.1. Antifungal 13.24.2. Hormonal 13.24.3. Ace Inhibitors 13.24.4. Antibiotic 13.24.5. Fondaparinux Drugs 13.25. Fondaparinux Drugs Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 13.25.1. Heparin Sodium 13.25.2. Enoxaparin Sodium 13.25.3. Dalteparin Sodium 13.25.4. Fondaparinux 13.26. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Forecast, By Application 13.26.1. Infectious Diseases 13.26.2. Gynecology 13.26.3. Cancer 13.26.4. Diabetes 13.26.5. Cardiology 13.26.6. Osteoporosis 13.26.7. Others 13.27. Asia Pacific Peptide and Anticoagulant Drugs Market Attractiveness Analysis 13.27.1. By Type 13.27.2. By Low Molecular Weight Heparin Type 13.27.3. By Application 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Peptide and Anticoagulant Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Peptide and Anticoagulant Drugs Market Overview 14.3. Middle East & Africa Peptide and Anticoagulant Drugs Market Value Share Analysis, By Type 14.4. Middle East & Africa Peptide and Anticoagulant Drugs Market Forecast, By Type 14.4.1. Antifungal 14.4.2. Hormonal 14.4.3. Ace Inhibitors 14.4.4. Antibiotic 14.4.5. Fondaparinux Drugs 14.5. Middle East & Africa Peptide and Anticoagulant Drugs Market Value Share Analysis, By Low Molecular Weight Heparin Type 14.6. Middle East & Africa Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 14.6.1.1. Heparin Sodium 14.6.1.2. Enoxaparin Sodium 14.6.1.3. Dalteparin Sodium 14.6.1.4. Fondaparinux 14.7. Middle East & Africa Peptide and Anticoagulant Drugs Market Value Share Analysis, By Application 14.8. Middle East & Africa Peptide and Anticoagulant Drugs Market Forecast, By Application 14.8.1. Infectious Diseases 14.8.2. Gynecology 14.8.3. Cancer 14.8.4. Diabetes 14.8.5. Cardiology 14.8.6. Osteoporosis 14.8.7. Others 14.9. Middle East & Africa Peptide and Anticoagulant Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Peptide and Anticoagulant Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Peptide and Anticoagulant Drugs Market Analysis, by Country 14.12. GCC Peptide and Anticoagulant Drugs Market Forecast, By Type 14.12.1. Antifungal 14.12.2. Hormonal 14.12.3. Ace Inhibitors 14.12.4. Antibiotic 14.12.5. Fondaparinux Drugs 14.13. GCC Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 14.13.1. Heparin Sodium 14.13.2. Enoxaparin Sodium 14.13.3. Dalteparin Sodium 14.13.4. Fondaparinux 14.14. GCC Peptide and Anticoagulant Drugs Market Forecast, By Application 14.14.1. Infectious Diseases 14.14.2. Gynecology 14.14.3. Cancer 14.14.4. Diabetes 14.14.5. Cardiology 14.14.6. Osteoporosis 14.14.7. Others 14.15. South Africa Peptide and Anticoagulant Drugs Market Forecast, By Type 14.15.1. Antifungal 14.15.2. Hormonal 14.15.3. Ace Inhibitors 14.15.4. Antibiotic 14.15.5. Fondaparinux Drugs 14.16. South Africa Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 14.16.1. Heparin Sodium 14.16.2. Enoxaparin Sodium 14.16.3. Dalteparin Sodium 14.16.4. Fondaparinux 14.17. South Africa Peptide and Anticoagulant Drugs Market Forecast, By Application 14.17.1. Infectious Diseases 14.17.2. Gynecology 14.17.3. Cancer 14.17.4. Diabetes 14.17.5. Cardiology 14.17.6. Osteoporosis 14.17.7. Others 14.18. Rest of Middle East & Africa Peptide and Anticoagulant Drugs Market Forecast, By Type 14.18.1. Antifungal 14.18.2. Hormonal 14.18.3. Ace Inhibitors 14.18.4. Antibiotic 14.18.5. Fondaparinux Drugs 14.19. Rest of Middle East & Africa Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 14.19.1. Heparin Sodium 14.19.2. Enoxaparin Sodium 14.19.3. Dalteparin Sodium 14.19.4. Fondaparinux 14.20. Middle East & Africa Peptide and Anticoagulant Drugs Market Forecast, By Application 14.20.1. Infectious Diseases 14.20.2. Gynecology 14.20.3. Cancer 14.20.4. Diabetes 14.20.5. Cardiology 14.20.6. Osteoporosis 14.20.7. Others 14.21. Middle East & Africa Peptide and Anticoagulant Drugs Market Attractiveness Analysis 14.21.1. By Type 14.21.2. By Low Molecular Weight Heparin Type 14.21.3. By Application 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Peptide and Anticoagulant Drugs Market Analysis 15.1. Key Findings 15.2. South America Peptide and Anticoagulant Drugs Market Overview 15.3. South America Peptide and Anticoagulant Drugs Market Value Share Analysis, By Type 15.4. South America Peptide and Anticoagulant Drugs Market Forecast, By Type 15.4.1. Antifungal 15.4.2. Hormonal 15.4.3. Ace Inhibitors 15.4.4. Antibiotic 15.4.5. Fondaparinux Drugs 15.5. South America Peptide and Anticoagulant Drugs Market Value Share Analysis, By Low Molecular Weight Heparin Type 15.6. South America Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 15.6.1.1. Heparin Sodium 15.6.1.2. Enoxaparin Sodium 15.6.1.3. Dalteparin Sodium 15.6.1.4. Fondaparinux 15.7. South America Peptide and Anticoagulant Drugs Market Value Share Analysis, By Application 15.8. South America Peptide and Anticoagulant Drugs Market Forecast, By Application 15.8.1. Infectious Diseases 15.8.2. Gynecology 15.8.3. Cancer 15.8.4. Diabetes 15.8.5. Cardiology 15.8.6. Osteoporosis 15.8.7. Others 15.9. South America Peptide and Anticoagulant Drugs Market Value Share Analysis, by Country 15.10. South America Peptide and Anticoagulant Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Peptide and Anticoagulant Drugs Market Analysis, by Country 15.12. Brazil Peptide and Anticoagulant Drugs Market Forecast, By Type 15.12.1. Antifungal 15.12.2. Hormonal 15.12.3. Ace Inhibitors 15.12.4. Antibiotic 15.12.5. Fondaparinux Drugs 15.13. Brazil Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 15.13.1. Heparin Sodium 15.13.2. Enoxaparin Sodium 15.13.3. Dalteparin Sodium 15.13.4. Fondaparinux 15.14. Brazil Peptide and Anticoagulant Drugs Market Forecast, By Application 15.14.1. Infectious Diseases 15.14.2. Gynecology 15.14.3. Cancer 15.14.4. Diabetes 15.14.5. Cardiology 15.14.6. Osteoporosis 15.14.7. Others 15.15. Mexico Peptide and Anticoagulant Drugs Market Forecast, By Type 15.15.1. Antifungal 15.15.2. Hormonal 15.15.3. Ace Inhibitors 15.15.4. Antibiotic 15.15.5. Fondaparinux Drugs 15.16. Mexico Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 15.16.1. Heparin Sodium 15.16.2. Enoxaparin Sodium 15.16.3. Dalteparin Sodium 15.16.4. Fondaparinux 15.17. Mexico Peptide and Anticoagulant Drugs Market Forecast, By Application 15.17.1. Infectious Diseases 15.17.2. Gynecology 15.17.3. Cancer 15.17.4. Diabetes 15.17.5. Cardiology 15.17.6. Osteoporosis 15.17.7. Others 15.18. Rest of South America Peptide and Anticoagulant Drugs Market Forecast, By Type 15.18.1. Antifungal 15.18.2. Hormonal 15.18.3. Ace Inhibitors 15.18.4. Antibiotic 15.18.5. Fondaparinux Drugs 15.19. Rest of South America Peptide and Anticoagulant Drugs Market Forecast, By Low Molecular Weight Heparin Type 15.19.1. Heparin Sodium 15.19.2. Enoxaparin Sodium 15.19.3. Dalteparin Sodium 15.19.4. Fondaparinux 15.20. Rest of South America Peptide and Anticoagulant Drugs Market Forecast, By Application 15.20.1. Infectious Diseases 15.20.2. Gynecology 15.20.3. Cancer 15.20.4. Diabetes 15.20.5. Cardiology 15.20.6. Osteoporosis 15.20.7. Others 15.21. South America Peptide and Anticoagulant Drugs Market Attractiveness Analysis 15.21.1. By Type 15.21.2. By Low Molecular Weight Heparin Type 15.21.3. By Application 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Celsus 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Baxter 16.3.3. Alkem Laboratories Limited 16.3.4. Hemmo Pharma 16.3.5. Biofer 16.3.6. Wockhardt 16.3.7. AmbioPharm 16.3.8. Bachem 16.3.9. Cadila Pharmaceuticals 16.3.10. Sun Pharmaceutical Industries 16.3.11. Pfizer 16.3.12. Abbott Laboratories 16.3.13. Leo Pharma 16.3.14. Aspen 16.3.15. Takeda 16.3.16. Teva 16.3.17. Sanofi 16.3.18. Eli Lilly 16.3.19. Novo Nordisk 16.3.20. Cipla Limited 16.3.21. Biocon Limited 17. Primary Key Insights

About This Report

Report ID 67227
Category Healthcare
Published Date July 2023
Updated Date
  • INQUIRE BEFORE BUYING